The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: Implications for anandamide uptake

British Journal of Pharmacology

Volumn 150, Issue 7, 2007, Pages 951-960

  Thors, L ^a   Alajakku, K ^a   Fowler, C J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Anandamide; Cellular uptake; Endocannabinoid; Endocytosis; Fatty acid amide hydrolase; Genistein

Indexed keywords

ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ETHANOLAMINE; FATTY ACID AMIDASE; GENISTEIN; METHANANDAMIDE; NYSTATIN; PROGESTERONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LINE; COMPETITIVE INHIBITION; DRUG POTENCY; DRUG UPTAKE; ENZYME ASSAY; ENZYME INHIBITION; INCUBATION TIME; ISOTOPE LABELING; MOLECULE; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BRAIN; CARBAMATES; CELL LINE, TUMOR; GENISTEIN; HYDROLYSIS; MICE; NYSTATIN; POLYUNSATURATED ALKAMIDES; PROGESTERONE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS;

EID: 34047223510     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707172     Document Type: Article

References (54)

1. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S-i, Itoh N et al. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595.
2. Bari M, Battista N, Fezza F, Finazzi-Agrò A, Maccarrone M (2005). Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280: 12212-12220.
3. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097.
4. Bisogno T, Hanu L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
5. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
6. Bojesen IN, Hansen HS (2003). Binding of anandamide to bovine serum albumin. J Lipid Res 44: 1790-1794.
7. Bojesen IN, Hansen HS (2005). Membrane transport of anandamide through resealed human red blood cell membranes. J Lipid Res 46: 1652-1659.
8. Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ (2004). A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods 60: 171-177.
9. Bowman CL, Yohe L, Lohr JW (1999). Enzymatic modulation of cell volume in C6 glioma cells. Glia 27: 22-31.
10. Brown DA, London E (2000). Structure and function of sphingolipid - and cholesterol-rich membrane rafts. J Biol Chem 275: 17221-17224.
11. Clapper JR, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2006). The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol Res 54: 341-344.
12. Day TA, Rakhshan F, Deutsch DG, Barker EL (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59: 1369-1375.
13. Deutsch DG, Chin SA (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791-796.
14. Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenbarger RA, Hillard CJ et al. (2001). The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J Biol Chem 276: 6967-6973.
15. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LG, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
16. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
17. Eisenthal R, Cornish-Bowden A (1974). The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J 139: 715-720.
18. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A et al. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101: 8756-8761.
19. Fowler CJ (2006). The cannabinoid system and its pharmacological manipulation - a review, with emphasis upon the uptake and hydrolysis of anandamide. Fund ClinPharmacol 20: 549-562.
20. Fowler CJ, Tiger G, Ligresti A, López-Rodíguez ML, Di Marzo V (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. Eur J Pharmacol 492: 1-11.
21. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR et al. (2004). Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol 143: 774-784.
22. Glaser S, Abumrad N, Fatade F, Kaczocha M, Studholme K, Deutsch D (2003). Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100: 4269-4274.
23. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102: 18620-18625.
24. Hillard CJ, Jarrahian A (2000). The movement of N- arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108: 123-134.
25. Hillard CJ, Jarrahian A (2003). Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140: 802-808.
26. Hillard CJ, Jarrahian A (2005). Accumulation of anandamide: evidence for cellular diversity. Neuropharmacology 48: 1072-1078.
27. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997). Accumulation of narachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631-638.
28. Holt S, Comelli F, Costa B, Fowler CJ (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol. 146: 467-476.
29. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol. 147: 281-288.
30. Jerman JC, Gray J, Brough SJ, Ooi L, Owen D, Davis JB et al. (2002). Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br J Anaesth 89: 882-887.
31. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG (2006). Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 281: 9066-9075.
32. Karlsson M, Påhlsson C, Fowler CJ (2004). Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur J Pharm Sci 22: 181-189.
33. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med. 9: 76-81.
34. Kozak KR, Marnett LJ (2002). Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66: 211-220.
35. Le PU, Nabi IR (2003). Distinct caveolae-mediated endocytic pathways target the golgi apparatus and the endoplasmic reticulum. J Cell Sci 116: 1059-1071.
36. Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G et al. (2004). Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 380: 265-272.
37. Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F et al. (2004). Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309: 745-757.
38. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker EL (2004). A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J Biol Chem 279: 41991-41997.
39. Moriello AS, Balas L, Ligresti A, Cascio MG, Duran M, Morera E et al. (2006). Development of the first potential covalent inhibitors of anandamide cellular uptake. J Med Chem 49: 2320-2332.
40. Oddi S, Bari M, Battista N, Barsacchi D, Cozzani I, Maccarrone M (2005). Confocal microscopy and biochemical analysis reveals spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell Mol Life Sci 62: 386-395.
41. Ortega-Gutiérrez S, Hawkins EG, Viso A, López- Rodríguez ML, Cravatt BF (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43: 8184-8190.
42. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A et al. (2003). The gerneral anesthetic propofol increases brain N-arachidonoylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 139: 1005-1013.
43. Patricelli MP, Cravatt BF (2001). Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitamins Hormones 62: 95-131.
44. Paylor B, Holt S, Fowler CJ (2006). The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res 54: 481-485.
45. Rakhshan F, Day TA, Blakely RD, Barker EL (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL2H3 cells. J Pharmacol Exp Ther 292: 960-967.
46. Ronesi J, Gerdeman GL, Lovinger DM (2004). Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24: 1673-1679.
47. 2 ethanolamide. J Pharmacol Exp Ther 301: 900-907.
48. Ruiz-Llorente L, Ortega-Gutiérrez S, Viso A, Sánchez MG, Sánchez AM, Fernández C et al. (2004). Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol 141: 457-467.
49. Sandberg A, Fowler CJ (2005). Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin. Chem Phys Lipids 134: 131-139.
50. Schmid PC, Zuzarte-Augustin ML, Schmid HHO (1985). Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 260: 14145-14149.
51. Thors L, Fowler CJ (2006). Is there a temperature-dependent uptake of anandamide into cells? Br J Pharmacol 149: 173-181.
52. Watanabe K, Ogi H, Nakamura S, Kayano Y, Matsunaga T, Yoshimura H et al. (1998). Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sci 62: 1223-1229.
53. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272: 21181-21186.
54. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sørgård M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.